title: Biological therapies in breast cancer: common toxicities and management strategies.
abstract: In recent years, a number of new molecules - commonly known as biological therapies - have been approved or are in late stages of regulatory evaluation for the treatment of advanced breast cancer. These innovative compounds have improved treatment efficacy and have probably contributed to the increase in survival length observed in some breast cancer subtypes. However, these agents are not deprived of toxicity, which can impair quality of life and may occasionally be life-threatening. In this article, we reviewed the most common toxicities associated with these drugs and provided a number of practical recommendations on their optimal clinical management.
authors.affiliation: Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo, 251, 5° andar, CEP 01246-000 São Paulo, SP, Brazil.
authors.forename: Romualdo
authors.initials: R
authors.lastname: Barroso-Sousa
authors.forename: Iuri A
authors.initials: IA
authors.lastname: Santana
authors.forename: Laura
authors.initials: L
authors.lastname: Testa
authors.forename: Débora
authors.initials: D
authors.lastname: de Melo Gagliato
authors.forename: Max S
authors.initials: MS
authors.lastname: Mano
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D001691:Biological Therapy / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D000077341:Lapatinib; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives; D011799:Quinazolines / Q000009:adverse effects; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D000068878:Trastuzumab
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D011799:Quinazolines; D000077341:Lapatinib; D008453:Maytansine; D000068258:Bevacizumab; D000068338:Everolimus; C485206:pertuzumab; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine; D020123:Sirolimus
keywords: ABC; AE; Adverse events; Bevacizumab; Breast cancer; CT; EGFR; Everolimus; FDA; Food and Drug Administration; HER2; LVEF; Lapatinib; Pertuzumab; QoL; RCC; T-DM1; Trastuzumab; Trastuzumab emtansine; Trastuzumab-emtansine; VEGF; advanced breast cancer; adverse event; computed tomography; epidermal growth factor receptor; human epidermal growth factor receptor type 2; left ventricular ejection fraction; mTOR; quality of life; renal cell cancer; the mammalian target of rapamycin; vascular endothelial growth factor